clinical trial · NCT04398524
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Squamous Cell Carcinoma of the OropharynxISA101b
brief summary
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
started
Jul 1, 2021
primary completion
Jun 30, 2024
completion
Dec 30, 2024
last updated
Jan 16, 2024
detailed description
This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response Rate in subjects who have progressed on prior anti-PD-1 therapy.
official title
A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol